Verici Dx plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRCDF research report →
About the company
Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection.
- CEO
- Sara jane Barrington
- IPO
- 2022
- Employees
- 19
- HQ
- Penarth, GB
Price Chart
- Market Cap
- $4.54M
- P/E
- -0.40
- P/S
- 2.34
- P/B
- 1.16
- EV/EBITDA
- -0.70
- Div Yield
- 0.00%
- Gross Margin
- 79.60%
- Op Margin
- -189.04%
- Net Margin
- -193.05%
- ROE
- -138.93%
- ROIC
- -91.21%
- Revenue
- $3.75M · 12.17%
- Net Income
- $-7,087,189 · -20.65%
- EPS
- $-0.01 · 64.40%
- Op Income
- $-6,935,897
- FCF YoY
- -35.28%
- 52W High
- $2.91
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.26
- Avg Volume
- 538.036
Get TickerSpark's AI analysis on VRCDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VRCDF coverage
Recent articles, reports, and earnings notes.
No research on VRCDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRCDF report →Similar companies
Peers in the same neighborhood.